Abiopharma

SEALSQ Issues CEO Letter to Shareholders

NeuroSense Issues CEO Letter to Shareholders

ComEd Restores Power to More Than 80 Percent of Customers Impacted by August 11 and 12 Storms

Clinical trial NCT06849869 updates: 1. completion date: 2028-06-30 → 2029-03-30 2. primary completion date: 2028-06-30 → 2029-01-30

Clinical trial NCT06873945 updates: 1. status: ACTIVE_NOT_RECRUITING → RECRUITING 2. completion date: 2026-12-21 → 2028-03-19 3. primary completion date: 2026-12-21 → 2028-03-19 4. enrollment: 550 → 1330 participants 5. enrollment type: ACTUAL → ESTIMATED

Clinical trial NCT06992544 updates: 1. completion date: 2026-07-01 → 2026-11-01 2. primary completion date: 2026-07-01 → 2026-11-01

Clinical trial NCT06252753 updates: 1. start date: 2023-12-20 → 2023-12-19 2. enrollment: 4490 → 4000 participants

Clinical trial NCT06269120 updates: 1. status: RECRUITING → COMPLETED 2. completion date: 2026-03-31 → 2026-05-05 3. primary completion date: 2026-03-31 → 2026-05-05 4. enrollment: 470 → 243 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT07166393 updates: 1. start date: 2026-05-01 → 2027-05-01 2. completion date: 2030-12-01 → 2031-12-01 3. primary completion date: 2030-02-01 → 2031-05-01

Clinical trial NCT06975787 updates: 1. completion date: 2029-09-09 → 2029-09-10 2. primary completion date: 2029-09-09 → 2029-09-10